Usted buscó: postmenopausis (Estonio - Inglés)

postmenopausis naistel
in post-menopausal women

emakaga postmenopausis naised
postmenopausal women with a uterus

osteoporoosi ravi postmenopausis naistel
treatment of osteoporosis in post-menopausal women

toremifeen on näidustatud postmenopausis patsientidel.
toremifene is recommended for postmenopausal patients.

toremifeeni on soovitatav kasutada postmenopausis patsientidel.
toremifene is recommended for postmenopausal patients.

tabel 4 murdude esinemissagedus postmenopausis naistel:
table 4

optruma on mõeldud kasutamiseks ainult postmenopausis naistel.
optruma is only for use in postmenopausal women.

adrovance on ette nähtud kasutamiseks ainult postmenopausis naistel.
adrovance is only intended for use in postmenopausal women.

metastaseerunud hormoonsõltuva rinnanäärme vähi hormoonravi valikpreparaat postmenopausis haigetel.
first line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.

osteoporoos (luu- urbnemus) meestel ja postmenopausis naistel.
osteoporosis (a disease that makes bones fragile), both in women who have been through the menopause and in men.

evista on näidustatud osteoporoosi raviks ja profülaktikaks postmenopausis naistel.
evista is indicated for the treatment and prevention of osteoporosis in postmenopausal women.

rasedus ja imetamine adrovance on ettenähtud kasutamiseks ainult postmenopausis naistel.
pregnancy and breast-feeding adrovance is only intended for use in postmenopausal women.

postmenopausis naistel vähendab strontsiumranelaat lülisamba- ja puusaluu murdude riski.
in postmenopausal women, strontium ranelate reduces the risk of fracture at the spine and at the hip.

alendronaat väldib luukoe hõrenemist postmenopausis olevatel naistel ja soodustab luukoe taastumist.
alendronate prevents the loss of bone that occurs in women after they have been through the menopause, and helps to rebuild bone.

basedoksifeeni 20 mg üksikannuse farmakokineetikat hinnati uuringus, kus osales 26 tervet postmenopausis naist.
the pharmacokinetics of a 20 mg single dose of bazedoxifene were evaluated in a study in 26 healthy postmenopausal women.

preotact’i kasutatakse osteoporoosi raviks postmenopausis naistel, kellel on suur risk luumurdude tekkeks.
preotact is used to treat osteoporosis in women past menopause with high risk of fractures.

kolm uuringut hõlmasid 1764 postmenopausis naist, keda raviti optruma ja kaltsiumiga või platseebo ja kaltsiumi lisandiga.
three trials included 1,764 postmenopausal women who were treated with optruma and calcium or calcium supplemented placebo.

konjugeeritud östrogeenide / basedoksifeeni ohutust hinnati 4868 postmenopausis naisel, kes osalesid viies iii faasi uuringus.
the safety of ce/bazedoxifene was evaluated in 4,868 post-menopausal women who participated in 5 phase 3 trials.

fablyn’i kasutamiseks lastel ja noorukitel puudub näidustus, sest see ravim on mõeldud ainult postmenopausis naistele.
there is no indication for fablyn in children and adolescents below 18 years of age since the medicinal product is for use in postmenopausal women only.

preotact on näidustatud osteoporoosi raviks kõrge luumurru tekke riskiastmega postmenopausis naistel (vt lõik 5.1).
preotact is indicated for the treatment of osteoporosis in postmenopausal women at high risk of fractures (see section 5.1).